Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00283049
Status:
TERMINATED
Last Update Posted:
2011-01-13
First Post:
2006-01-26
Brief Title:
Insulin Glargine Injection Treatment in Place of Thiazolidinedione TZD Sulfonylurea or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus T2DM Adult Subjects With Unsatisfactory Control
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Safety and Efficacy of Insulin Glargine Injection rDNA Origin Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control
Status:
TERMINATED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to technical issues relating to the Electronic diary data
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the change in hemoglobin A1c HbA1c from baseline to Week 12 between the 3 treatment arms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None